Serezin™

Boswellia serrata / Zingiber officinale
Evidence Level
Limited
1 Clinical Trial
4 Documented Benefits
2/5 Evidence Score

Serezin™ is PLT Health Solutions' patented blend of Boswellia serrata and ginger (Zingiber officinale) extracts — developed specifically to address the sleep-pain connection. In a 4-week randomized, double-blind, placebo-controlled trial in 60 adults aged 50–70, participants reported less nighttime discomfort, better sleep quality, and easier morning waking. Important context: that trial was run and reported by the manufacturer and released as a conference abstract, so it is not among the peer-reviewed references cited on this page. The published, PubMed-indexed evidence below covers the individual components (Boswellia and ginger) and measures pain rather than sleep.

Studied Dose 300 mg/day — the dose used in the manufacturer's 4-week trial, which reported changes within 1 week and the largest effects at 4 weeks (company-reported, not peer-reviewed)
Active Compound Proprietary Boswellia serrata + Zingiber officinale extract complex — Serezin™ by PLT Health Solutions (300 mg/serving)

Benefits

Restorative sleep improvement

In the manufacturer's own 4-week trial (reported by PLT Health Solutions, released as a conference abstract and not among the peer-reviewed references cited on this page), the Serezin group reported a 64% greater improvement in restorative sleep quality than placebo. This figure has not been independently published, peer-reviewed, or replicated. Unlike melatonin or sedatives, Serezin is proposed to work by easing the discomfort that disrupts sleep rather than by inducing sedation; this is the rationale behind the formula rather than a separately demonstrated mechanism.

Nighttime and daytime pain reduction

In the manufacturer's 4-week trial (not among the peer-reviewed references cited on this page), discomfort scores improved by Day 7, and by Day 28 the Serezin group reported a 2.6x greater reduction in nighttime discomfort and a 75% greater reduction in daytime discomfort than placebo. The cited peer-reviewed studies below support the individual components for occasional aches and joint comfort: Boswellia extract improved knee pain and function in adults over 40 (Pérez-Piñero 2023) and in knee osteoarthritis (Sengupta 2008), and ginger reduced exercise-induced muscle pain (Black 2010). None of those trials measured sleep.

Sleep onset and quality

In the manufacturer's 4-week trial, subjects reported 85% greater improvement in ease of falling asleep and 93% greater improvement in sleep quality versus placebo at Day 14 on the Leeds Sleep Evaluation Questionnaire, with similar results in men and women; a women-only analysis was presented as an abstract in the SLEEP 2025 supplement. These are company-reported, self-rated questionnaire outcomes from a conference abstract rather than a peer-reviewed publication, and they are not among the references cited on this page.

Mood and morning alertness

In the manufacturer's 4-week trial, Serezin subjects reported a 2.2x improvement in overall mood scores along with easier waking and greater morning alertness. These are self-reported secondary outcomes from a company-run study that is not among the peer-reviewed references cited on this page, and they have not been independently confirmed.

Mechanism of action

1

Boswellic acid anti-inflammatory activity

Boswellia serrata extract inhibits 5-lipoxygenase (5-LOX), the enzyme that produces pro-inflammatory leukotrienes responsible for joint and soft tissue inflammation. This targeted anti-inflammatory action reduces the chronic low-grade pain that disrupts sleep quality in aging adults.

2

Ginger COX inhibition and analgesic activity

Zingiber officinale constituents (gingerols, shogaols) inhibit cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin-mediated pain signaling. Combining 5-LOX inhibition (Boswellia) with COX inhibition (ginger) is proposed to cover more of the inflammatory pain pathway than either ingredient alone. This synergy is a mechanistic rationale drawn from the separate component studies; no published head-to-head human trial has compared the blend against its individual components.

3

Circadian rhythm preservation

The rationale is that easing discomfort, rather than forcing sedation, lets normal sleep patterns take their own course. No polysomnography or other objective sleep-architecture or circadian measurements have been published for Serezin — the reported sleep outcomes are self-rated questionnaire scores — so any effect on sleep stages remains a proposed rationale rather than a measured result.

Clinical trials

1
Boswellia serrata (LI51202F1, Serezin Component) DOMS & Recovery

10-day randomized, double-blind, placebo-controlled study of the Boswellia component (LI51202F1) and exercise-induced muscle soreness. (Manufacturer-conducted; PLT Health Solutions.) Note: this is a COMPONENT study — it did not test the finished Serezin blend and did not measure any sleep outcome. No trial of the finished Serezin blend has been published in peer-reviewed, PubMed-indexed form.

50 recreationally active men (mean age 28 ± 4) randomized to 60 mg standardized B. serrata extract LI51202F1 (the same extract used in Serezin™, water-soluble, ≥76% AKBA) or placebo for 10 days (6 days before, day of, and 3 days after downhill running). DOMS induced by three 15-min downhill running episodes on a 10% declined treadmill. Conducted by PLT Health Solutions and Yalamanchi Hospital and Research Centre.

B. serrata significantly attenuated muscle and joint soreness (VAS) and accelerated recovery of leg-extension 1RM strength after eccentric exercise vs placebo. The full Serezin® product (Boswellia + ginger) was also tested in a separate 4-week, 60-person 50-70 yr trial in adults with sleep disturbance from aches/pains; the abstract appeared in sleep 2025 Supplement (doi 10.1093/sleep/zsaf090.0941, conference abstract — not individually PubMed-indexed). PLT-reported Serezin findings: 64% greater restorative sleep improvement at 4 weeks, 2.6× reduction in nighttime discomfort, 75% reduction in daytime discomfort, 2.2× mood improvement. The full Serezin paper has not yet been published in PubMed-indexed peer-reviewed form. This study supports the Boswellia component's effect on exercise-related soreness and recovery only. It does not test sleep, and it does not test the finished Boswellia-plus-ginger Serezin blend.

Side effects and drug interactions

Common Potential side effects

Reported as well tolerated with no serious adverse events in the manufacturer's 4-week trial; that safety report has not been published in peer-reviewed form, and no long-term (beyond 4 weeks) safety data are available
GI discomfort possible with high-dose Boswellia in sensitive individuals — standard doses well tolerated
Mild blood thinning effect from ginger — use caution before surgery

Important Drug interactions

NSAIDs (ibuprofen, naproxen) — complementary but potentially additive anti-inflammatory effects; monitor
Anticoagulants (warfarin) — ginger mildly inhibits platelet aggregation; monitor INR
Antihypertensive medications — ginger may mildly lower blood pressure; monitor

Frequently asked questions about Serezin™

What is Serezin?

Serezin™ is PLT Health Solutions' patented blend of Boswellia serrata and ginger (Zingiber officinale) extracts — developed specifically to address the sleep-pain connection.

What is Serezin used for?

Serezin is researched primarily for Sleep Health. In the manufacturer's own 4-week trial (reported by PLT Health Solutions, released as a conference abstract and not among the peer-reviewed references cited on this page), the Serezin group reported a 64% greater improvement in restorative…

What is the recommended dosage of Serezin?

The clinically studied dose is 300 mg/day — the dose used in the manufacturer's 4-week trial, which reported changes within 1 week and the largest effects at 4 weeks (company-reported, not peer-reviewed) Always follow the product label and check with a healthcare provider for personal advice.

Is Serezin safe, and does it have side effects?

For most healthy adults, Serezin is well tolerated at studied doses. Reported effects can include: Reported as well tolerated with no serious adverse events in the manufacturer's 4-week trial; that safety report has not been published in peer-reviewed form, and no long-term (beyond 4 weeks) safety data are available GI discomfort possible with high-dose Boswellia in sensitive… It may also interact with some medications. Serezin is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Serezin interact with any medications?

Possible interactions include: NSAIDs (ibuprofen, naproxen) — complementary but potentially additive anti-inflammatory effects; monitor Anticoagulants (warfarin) — ginger mildly inhibits platelet aggregation; monitor INR If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Serezin?

NutraSmarts rates the evidence for Serezin as Limited (2 out of 5). It is backed by 1 clinical trial and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Pérez-Piñero S, Muñoz-Carrillo JC, Victoria-Montesinos D, García-Muñoz AM, Andreu-Caravaca L, Gómez M, et al. Efficacy of Boswellia serrata Extract and/or an Omega-3-Based Product for Improving Pain and Function in People Older Than 40 Years with Persistent Knee Pain: A Randomized Double-Blind Controlled Clinical Trial. Nutrients. 2023;15(17):3848. doi: 10.3390/nu15173848.PubMedUsed to support: Double-blind RCT: Boswellia serrata extract significantly improved pain and physical function in adults over 40 with persistent knee pain vs. placebo—supports the Boswellia component for joint comfort. COMPONENT EVIDENCE: this trial tested Boswellia extract (with or without omega-3) and measured knee pain and physical function — it did not test the Serezin blend and did not measure any sleep outcome.
  2. Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, Dey D, Raychaudhuri SP. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85. doi: 10.1186/ar2461.PubMedUsed to support: Double-blind RCT (90 days): Boswellia serrata AKBA-enriched extract (5-Loxin) significantly reduced pain and improved physical function vs. placebo within 7 days, with improvements growing over 90 days—supports the Boswellia component for joint comfort. COMPONENT EVIDENCE: this trial tested the 5-Loxin AKBA-enriched Boswellia extract in knee osteoarthritis with pain and function endpoints — it did not test the Serezin blend and measured no sleep outcome.
  3. Black CD, Herring MP, Hurley DJ, O'Connor PJ. Ginger (Zingiber officinale) reduces muscle pain caused by eccentric exercise. J Pain. 2010;11(9):894-903. doi: 10.1016/j.jpain.2009.12.013.PubMedUsed to support: RCT: ginger supplementation significantly reduced muscle pain from eccentric exercise—supports the ginger component for exercise-related muscle soreness. COMPONENT EVIDENCE: this study tested ginger alone, not the combined Serezin formula, in young exercising adults — it measured eccentric-exercise muscle pain and no sleep outcome.
  4. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011;50(6):349-69. doi: 10.2165/11586800-000000000-00000.PubMedUsed to support: Comprehensive review of Boswellia serrata clinical and pharmacological data, including its 5-lipoxygenase inhibitory mechanism underlying anti-inflammatory and pain-reducing effects—provides mechanistic grounding for the Boswellia component. BACKGROUND REVIEW, not a clinical trial: it summarizes in vitro, preclinical and pharmacokinetic data for Boswellia serrata and contains no sleep data and no data on the Serezin blend.